newsfilter
← Latest News
PR Newswire·

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today